Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management
Year: 2007
Type: review
Abstract: Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.
Source: Hepatology
DOI: 10.1002/hep.21698
Institutions: University of Michigan, Lyon 1 Université, Inserm, Hospices Civils de Lyon, Victorian Infectious Diseases Reference Laboratory, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Hôpitaux Universitaires Henri-Mondor, Chang Gung University, Chang Gung Memorial Hospital, Nagoya City University, Los Alamos National Laboratory
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Institut National de la Santé et de la Recherche Médicale, National Institutes of Health, Japan Society for the Promotion of Science, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases
OpenAlex ID: W2016449892